IRIS Institutional Research Information System - OPENBS Open Archive UniBS

PECORELLI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.759
EU - Europa 3.981
AS - Asia 2.904
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 16
SA - Sud America 16
OC - Oceania 13
Totale 18.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.700
CN - Cina 1.427
UA - Ucraina 1.289
SG - Singapore 623
IT - Italia 608
DE - Germania 543
HK - Hong Kong 484
PL - Polonia 394
FI - Finlandia 356
IE - Irlanda 192
TR - Turchia 180
RU - Federazione Russa 169
GB - Regno Unito 162
IN - India 105
FR - Francia 101
SE - Svezia 57
CA - Canada 52
EE - Estonia 24
NL - Olanda 20
BE - Belgio 19
MU - Mauritius 18
VN - Vietnam 18
EU - Europa 16
AU - Australia 12
AT - Austria 11
BR - Brasile 11
IR - Iran 9
ID - Indonesia 8
CZ - Repubblica Ceca 7
LT - Lituania 7
KG - Kirghizistan 6
KR - Corea 5
MX - Messico 5
AZ - Azerbaigian 4
LK - Sri Lanka 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
CH - Svizzera 3
EG - Egitto 3
JP - Giappone 3
LU - Lussemburgo 3
MA - Marocco 3
PT - Portogallo 3
SA - Arabia Saudita 3
BD - Bangladesh 2
BY - Bielorussia 2
CL - Cile 2
IL - Israele 2
IQ - Iraq 2
KZ - Kazakistan 2
LV - Lettonia 2
TH - Thailandia 2
AL - Albania 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
ES - Italia 1
GR - Grecia 1
JO - Giordania 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MS - Montserrat 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 18.716
Salva come PNG Salva come JPEG
Città #
Fairfield 1.662
Woodbridge 1.636
Houston 1.108
Jacksonville 914
Ashburn 900
Ann Arbor 800
Wilmington 761
Seattle 695
Cambridge 644
Hong Kong 466
Singapore 422
Warsaw 393
Chandler 364
Nanjing 353
Princeton 353
New York 219
Dearborn 212
Dublin 192
Beijing 181
Helsinki 170
Istanbul 157
Nanchang 128
Moscow 100
San Diego 90
Shenyang 87
Des Moines 86
Changsha 67
Hebei 67
Kunming 66
Milan 65
Shanghai 65
Jiaxing 58
Jinan 57
Los Angeles 57
Tianjin 48
Toronto 45
Brescia 43
Hangzhou 41
London 29
Ningbo 25
Tallinn 24
Zhengzhou 23
Verona 22
Monmouth Junction 20
Rome 20
Brussels 19
Lancaster 18
Lanzhou 18
Taizhou 18
Hefei 17
Washington 17
Dong Ket 16
Norwalk 16
Orange 16
Pune 16
Central 14
San Francisco 14
Taiyuan 12
Guangzhou 11
Nuremberg 11
Fuzhou 10
Munich 10
Ardabil 9
Falkenstein 9
Haikou 9
Kocaeli 9
Leawood 8
Kilburn 7
New Bedfont 7
San Mateo 7
Vienna 7
Bishkek 6
Boardman 6
Changchun 6
Melbourne 6
Amsterdam 5
Chicago 5
Dalmine 5
Jakarta 5
Mexico City 5
Phoenix 5
Augusta 4
Baku 4
Colombo 4
Hanover 4
Indiana 4
Lappeenranta 4
Newark 4
Prezzo 4
Southwark 4
São Paulo 4
Trani 4
Arezzo 3
Auburn Hills 3
Bologna 3
Brno 3
Chiari 3
Chongqing 3
Frankfurt am Main 3
Kaunas 3
Totale 14.382
Salva come PNG Salva come JPEG
Nome #
Bambini pretermine: nati per vivere 301
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 270
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 264
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. 260
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 230
OVEREXPRESSION OF CLOSTRIDIUM PERFRINGENS ENTEROTOXIN RECEPTORS CLAUDIN-3 AND CLAUDIN-4 IN UTERINE CARCINOSARCOMAS. 185
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 162
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 155
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women 150
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 150
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 146
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 145
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 145
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 143
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 143
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin 143
Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). 141
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 140
Consolidation therapies revisited: weekly paclitaxel 139
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 137
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 136
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 136
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 136
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 135
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 132
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 132
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 130
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 130
Carcinoma of the Fallopian tube 130
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 129
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 128
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 127
Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board 126
Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. 125
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 123
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 122
Chlamydia trachomatis genotypes in school adolescents, Italy 122
Mammaglobin B expression in human endometrial cancer 122
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 121
ADVANCES IN DENDRITIC-CELL-BASED THERAPEUTIC VACCINES FOR CERVICAL CANCER. 120
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 119
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 118
Mental health and the global agenda. 118
Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency 118
Replacement therapy for breast cancer survivors. A pilot study 118
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight 117
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 116
Gestational trophoblastic diseases 116
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 115
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 115
Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model 115
Toward appropriate criteria in medication adherence assessment in older persons: Position Paper 114
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. 113
Revised FIGO staging for carcinoma of the vulva, cervix, andendometrium. 113
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 113
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 113
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 112
Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference 112
Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in Uterine Serous Papillary Cancer 111
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. 110
Carcinoma of the Fallopian tube 110
Prescription drug use among older adults in Italy: A country-wide perspective 110
Early stage cervical cancer: adjuvant treatment in negative lymph node cases. 109
Scaling up health knowledge at European level requires sharing integrated data: An approach for collection of database specification 109
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 108
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS) 108
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer 107
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 107
Early stage ovarian cancer: the Italian contribution to clinical research. An update 107
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 107
High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA) 106
History of the FIGO cancer staging system 105
New development of the FIGO staging system. 105
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 105
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 104
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 104
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 104
Hormone replacement therapy in breast cancer 104
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 103
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 103
Neoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy 102
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 102
Interval debulking surgery in advanced epithelial ovarian cancer 102
Carcinoma of the corpus uteri 102
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. 101
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. 101
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 101
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 101
Hearing loss and cognitive decline in older adults: Questions and answers 101
Revised FIGO staging for carcinoma of the cervix. 100
hI-con1, a factor VII-IgGFc chimeric protein targetingtissue factor for immunotherapy of uterine serous papillary carcinoma. 100
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 99
Gestational trophoblastic diseases 99
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 98
Optimizing gemcitabine regimens in ovarian cancer. 98
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 97
The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervicalcancer cells. 97
Staging of gynecologic malignancies 97
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. 95
High serum levels of interleukin-6 in endometrialcarcinoma are associated with uterine serous papillary histology, a highlyaggressive and chemotherapy-resistant variant of endometrial cancer. 95
Totale 12.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.270
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.270
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.320 0 0 0 0 0 0 0 0 370 566 110 274
2020/20212.785 64 363 116 345 126 334 135 323 360 263 271 85
2021/20221.537 124 236 13 71 11 106 77 88 77 292 123 319
2022/20231.190 240 30 50 69 83 343 10 94 153 11 52 55
2023/20241.512 78 35 145 108 82 358 49 60 330 57 20 190
2024/20251.476 19 31 10 379 308 265 188 77 199 0 0 0
Totale 19.157